about
Update in genetic susceptibility in melanomaTERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.TERT gene amplification is associated with poor outcome in acral lentiginous melanoma.Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancerGenome-wide association study identifies a new melanoma susceptibility locus at 1q21.3Genome-wide association study identifies three new melanoma susceptibility loci.A variant in FTO shows association with melanoma risk not due to BMIDermoscopic criteria and basal cell carcinoma.Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.Validity and Reliability of Dermoscopic Criteria Used to Differentiate Nevi From Melanoma: A Web-Based International Dermoscopy Society Study.An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study.Growth-Curve Modeling of Nevi With a Peripheral Globular PatternCloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region.In vivo assessment of acute UVB responses in normal and Xeroderma Pigmentosum (XP-C) skin-humanized mouse models.Genetic testing for melanoma.A DNA methylation fingerprint of 1628 human samples.Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.The effect on melanoma risk of genes previously associated with telomere length.Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona.Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindredsFollow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method.Dermoscopy of early recurrent basal cell carcinoma.New dermoscopic pattern in actinic keratosis and related conditions.Dermoscopic rosettes as a clue for pigmented incipient melanoma.Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regionsIdentification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes?Histologic features of melanoma associated with CDKN2A genotype.Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet.Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.Vitiliginous alopecia masquerading as frontal fibrosing alopeciaClinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain.Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanomaChromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene.Management of high-risk and advanced basal cell carcinoma.Selection criteria for genetic assessment of patients with familial melanomaMethods of Melanoma Detection.High nevus counts confer a favorable prognosis in melanoma patients.
P50
Q26778756-3586F49A-E015-487D-AA8C-5FDE7199B3F3Q27853068-3A1A77CB-CF91-4144-9F9E-501831A245F5Q27853071-C7A59678-F986-4450-97A4-FBBA29F14A26Q28238393-30017C09-C21E-4C7B-890B-9DBF4682015AQ28943520-666D2270-C197-4D1A-B79E-6FC5E7D3B4A7Q29416994-C4CD933B-3A9F-4F5F-8476-FBFD2C124E46Q29417157-DAE892F3-3ABF-43D5-9FE8-66920EFACB73Q30249225-369BFCF0-9E9E-49FD-A83B-50171C867AA3Q33232622-B5601431-5CAC-4AE3-8075-1997030495F2Q33368188-83D5B58E-FA8A-4F08-880E-B017B934AE7DQ33370019-F5D56FF3-0BB1-4660-9AD8-C8C5867887ECQ33746014-F848808F-1A3C-4743-96EC-2A20FEE64AAEQ33785471-DECCABE8-7C72-4F12-9F9B-7DDF87C1AC5BQ33832930-183D4B66-97E4-41A4-9314-7EE0C1550C18Q33881212-0273A2E0-3556-456F-950E-198BB45A570FQ34033487-29029523-D9AB-4FA0-8035-CA884F23A249Q34158316-FDEB3C06-B63B-471F-9CD1-61558F554B9CQ34187360-7AE7A160-9E22-4B5D-B744-C2D7CA0925CAQ34212766-1B247817-5AD5-4578-8AE3-F1067D2DE0A8Q34333988-FA28EF5B-443C-44F7-B62D-30ED10661BBAQ34588331-0776CBDA-F1D7-43EE-AEFD-5E37E760C2E6Q34602917-7E505A11-B299-4E68-ABD4-2948B69439E9Q34609753-77807162-D871-435C-B299-C855535E05A0Q34696792-36C50063-0A12-4E67-9F4E-7AC1A75171A9Q34828452-60A86A4B-3AEB-4416-AFC3-2D0A0B7C9D1CQ34986971-A2288CB2-999E-473E-B1DA-8C78AC0B813DQ35072213-0541BC2E-D701-48D5-9777-D4A9C674BED0Q35083710-C07BA5B4-0AAE-41B2-90A9-41E2FDCF7E48Q35084720-8B952C48-F738-4B6F-834B-F80ACCDA004BQ35097007-42C94031-DFE9-463D-B7A3-180938DA35E5Q35122794-3117C26D-8C34-49FF-8AD6-F39D451A81ADQ35180844-97876BED-D2F5-4E55-9B43-914F0B28032CQ35293594-BE9C9DB8-47A9-493A-B212-F91ACC9735D6Q35446785-8C1C9765-B1E4-4069-A98D-FF59E81131BAQ35549114-22C31FC0-914A-4B3D-98A7-37D958BDC58DQ35644518-5A4D8FCA-8F75-432C-804F-258D1E684DDBQ35829546-261927CB-B7C0-4F93-9676-9FAA51823FEFQ35840024-E00800B8-B49F-4209-B53C-34105210FFE6Q35851289-8DC2412B-8AED-4F43-95F3-E30BD31E5AD8Q35855182-8190BFB5-C92C-4D52-84B3-1505863812F0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Susana Puig
@ast
Susana Puig
@en
Susana Puig
@es
Susana Puig
@nl
Susana Puig
@sl
type
label
Susana Puig
@ast
Susana Puig
@en
Susana Puig
@es
Susana Puig
@nl
Susana Puig
@sl
prefLabel
Susana Puig
@ast
Susana Puig
@en
Susana Puig
@es
Susana Puig
@nl
Susana Puig
@sl
P214
P950
P106
P1580
P21
P214
P31
P3835
susana-puig
P496
0000-0003-1337-9745
P734
P735
P7859
viaf-87336020